403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Oncolytics Biotech Inc
(MENAFN- Baystreet) 09:48 AM EST - Oncolytics Biotech Inc : Announces it will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in ChicagoMay 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic cancer characterized by its poor prognosis and limited treatment options. Oncolytics Biotech Inc
shares T are trading off $0.02 at $0.76.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment